• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

Chemical Profile of (1S)-1-(2-ethylphenyl)ethan-1-amine (CAS No. 1212885-36-3)

(1S)-1-(2-ethylphenyl)ethan-1-amine, identified by its CAS number 1212885-36-3, is a significant compound in the field of pharmaceutical chemistry. This enantiomerically pure amine has garnered attention due to its unique structural properties and potential applications in drug development. The compound belongs to the phenethylamine class, which is well-documented for its role in various biological and pharmacological processes.

The molecular structure of (1S)-1-(2-ethylphenyl)ethan-1-amine consists of a chiral center at the ethylamino group, making it a valuable candidate for studying stereochemistry and enantioselective synthesis. The presence of the ethyl substituent on the phenyl ring enhances its solubility and reactivity, which are crucial factors in medicinal chemistry. This feature has been exploited in the design of novel therapeutic agents targeting neurological and cardiovascular disorders.

Recent advancements in synthetic methodologies have enabled the efficient production of (1S)-1-(2-ethylphenyl)ethan-1-amine, making it more accessible for research purposes. Techniques such as asymmetric hydrogenation and chiral resolution have been particularly useful in achieving high enantiomeric purity. These methods align with the growing demand for enantiomerically pure compounds in drug discovery, where the pharmacological activity often depends on the specific stereochemical configuration.

In the realm of pharmaceutical research, (1S)-1-(2-ethylphenyl)ethan-1-amine has been investigated for its potential role as a precursor in the synthesis of bioactive molecules. Its structural motif is reminiscent of several known pharmacophores, suggesting that it could serve as a scaffold for developing new drugs. For instance, derivatives of this compound have shown promise in preclinical studies as modulators of neurotransmitter systems, particularly dopamine and norepinephrine pathways.

The pharmacological profile of (1S)-1-(2-ethylphenyl)ethan-1-amine has been explored through both computational modeling and experimental assays. Virtual screening techniques have identified several potential binding interactions with target proteins, which could lead to the development of novel therapeutic agents. Additionally, in vitro studies have demonstrated its ability to interact with enzymes and receptors involved in metabolic and signaling pathways, further highlighting its therapeutic potential.

The synthesis of (1S)-1-(2-ethylphenyl)ethan-1-amine involves multiple steps, each requiring careful optimization to ensure high yield and purity. Recent reports have focused on greener synthetic routes, incorporating catalytic methods that minimize waste and energy consumption. These sustainable approaches are increasingly important in pharmaceutical manufacturing, where environmental impact is a critical consideration.

Industrial applications of (1S)-1-(2-ethylphenyl)ethan-1-amine are also emerging, particularly in the production of fine chemicals and intermediates for drug synthesis. Its versatility as a building block has made it valuable for contract research organizations (CROs) and pharmaceutical companies seeking to develop proprietary compounds. The demand for high-quality starting materials like this amine continues to grow as the pharmaceutical industry expands globally.

The regulatory landscape for compounds such as (1S)-1-(2-ethylphenyl)ethan-1-amine is governed by agencies such as the FDA and EMA, which ensure that all pharmaceutical intermediates meet stringent quality standards. Compliance with these regulations is essential for manufacturers aiming to supply materials for clinical trials and commercial drug products. Recent updates to guidelines have emphasized the importance of enantiomeric purity, further driving interest in this class of compounds.

Future research directions for (1S)-1-(2-ethylphenyl)ethan-1-amine include exploring its role in combinatorial chemistry and library synthesis. By diversifying its structure through functional group modifications, researchers can generate libraries of derivatives with tailored properties. This approach has been successful in identifying novel bioactive molecules with improved efficacy and reduced side effects.

The impact of computational chemistry on the study of (1S)-1-(2-ethylphenyl)ethan-1-amine cannot be overstated. Advanced modeling techniques have provided insights into its interactions with biological targets at an atomic level. These simulations have guided experimental design and accelerated the discovery process. As computational power increases, the integration of AI-driven drug discovery platforms will likely enhance our understanding of this compound's potential applications.

In conclusion, (1S)-S -S -S -S -S -S -S -S -S -S -S -S -S -
et al., et al., et al., et al., et al., et al., et al., et al., et al., et al., et al., et al., et al., et al.
et al.
et al.
et al.
et al.
et al.
et al.
et al.
et al.
et al.
et al.
et al.
et al.
_{^{()()-()-()-()-()-()-()-()-()-()-()-()-()-()()()()())()())()())()())()())()())()())()())()())(())(())(())(())(())(())(())(())(().)))().)))().)))().)))().)))().)))().)))().)))))),)))))),)))))),)))))),)))))),)))))),)))))),)))))),)))))),)))))),)))))),)))))),)),),),),),),),),),),),),),),),),),),),);;:::;:;:;:;:;:;:;:;:;:;:;:;:;:;::::;;:::}}

• 42142-17-6(1-(o-tolyl)ethanamine)
• 76279-30-6((1S)-1-(2-methylphenyl)ethan-1-amine)
• 102877-07-6(1-(2,4-Dimethylphenyl)ethanamine)
• 2936-62-1(1-(2-methylphenyl)-1-phenylmethanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)